For immediate release
September, 2007

Principal Investigator:
Robert Lowery, PhD
BellBrook Labs
5500 Nobel Drive, Suite 250
Madison, WI 53711
866-313-7881
bob.lowery@bellbrooklabs.com

BellBrook Labs awarded an NINDS Phase I SBIR Grant toward developing assays for regulators of G-protein signaling

The National Institute of Neurological Disorders and Stroke has awarded BellBrook Labs a $200,000 Phase I Small Business Innovative Research grant (R43 NS59082) toward developing assays for regulators of G-protein signaling. Over half of current drugs exert their effects through a family of proteins called G-protein-coupled receptors. The targeting of these receptors has been especially useful for the development of drugs used to treat neurological disorders such as schizophrenia, depression and Parkinson's disease. To accelerate discovery of more selective therapies for these and other diseases, BellBrook Labs is developing novel screening assays for a family of proteins called "regulators of G-protein signaling" (RGS) that modulate the effects of GPCR ligands in a tissue-specific manner.

BellBrook Labs develops high throughput screening tools that accelerate the discovery of more effective therapies. The Transcreener HTS assay platform technology is based on the homogenous immunodetection of the nucleotide product of an enzyme reaction. The result is a robust, generic assay platform for the detection of entire families of drug targets. The expanding Transcreener platfrom now includes universal assays for the detection of ADP, AMP, GMP and UDP, which assay the major enzyme families of kinases, phosphodiesterases and glycosyltransferases, along with ATPases, emerging targets and enzymes that are difficult to assay.

Contact us at 866.313.7881 or info@bellbrooklabs.com for more information or to order the Transcreener UGT Far Red Assay.

Biology at Work